Latest news in cancer
Lymphoma: Pembrolizumab treatment approved
On June 12-13, FDA approved two new indications for K drug, just the day before the K drug was approved for the treatment of cervical cancer. One day later,...
Researchers discover a new mechanism of lymphoma resistance
In the United States, more than 70,000 people are diagnosed with non-Hodgkin’s lymphoma each year, which is caused by excessive proliferation of immune...
Progress in lymphoma immunotherapy
In recent years, the effect of immune checkpoint inhibitors on the treatment of Hodgkin’s lymphoma (HL) is impressive, but the disease still needs to be...
Genetic research solves 30-year leukemia mystery
Researchers at the University of California, San Francisco and St. Jude Children ’s Research Hospital in Tennessee have solved medical mysteries decades ago,...
Leukemia drug recognized by FDA as a breakthrough therapy
The FDA has granted its breakthrough drug quizartinib a breakthrough treatment. Quizartinib is a FLT3 inhibitor under investigation for the...
FDA updates medication regimen for chronic lymphocytic leukemia
The US Food and Drug Administration approved Venetoclax (Venclexta) combined with rituximab (VenR) for the treatment of patients with chronic lymphocytic...
The combination of two monoclonal antibodies for the treatment of lymphoma is 50% effective
According to a multi-center clinical trial led by researchers at the Stanford University School of Medicine, a new type of immunotherapy seems to be safe for...
Chemotherapy and immunotherapy combinations for the treatment of leukemia
According to the results of the second phase of the study, the combination of standard-care chemotherapy drug azacitidine and the immune checkpoint inhibitor...
FDA approves first rituximab biosimilar to treat lymphoma
On November 28, FDA approved the first rituximab (Rituxan, rituximab) biosimilar, Truxima (rituximab-abbs, Celltrion Inc.) for non-Hodgkin’s lymphoma...
The first monotherapy for leukemia received FDA approval
The US FDA has approved gilteritinib ( Xospata ) for the treatment of adult patients with FLT3 mutation-positive relapse or...
Compared with chemotherapy and immunization, ibrutinib is more effective in treating elderly leukemia
The results of a multi-center phase III clinical trial showed that if elderly patients with chronic lymphocytic leukemia ( CLL ) are...
Combination therapy for the treatment of leukemia
Venetoclax (Venclexta) and rituximab (Rituxan) are used in combination with relapsed / refractory chronic lymphocytic leukemia ( CLL ), resulting in a...
Need help? Our team is ready to assist you.
We wish a speedy recovery of your dear and near one.